Dr. Philip M. Hansbro is currently the deputy director of the Centenary
Institute and Chair of Inflammation at the University of Technology Sydney.
Previously, he held academic posts at Newcastle University, University of
Cambridge and Australian National University. He obtained his bachelor’s degree
(Honours) from Sheffield Hallam University, UK, and his Ph.D. from the
University of Leeds, UK. Prof. Dr. Hansbro is one of the world’s leading
respiratory researchers with a focus on how inflammation contributes to the
progression of chronic lung diseases. As director of the Centenary UTS Centre
for Inflammation, he has led the identification of new treatments for chronic
obstructive pulmonary disease (emphysema), severe asthma, pulmonary fibrosis,
influenza, and COVID-19. Prof. Dr. Hansbro has been the world’s top-ranked researcher
on emphysema on SciVal over the past five years. He has published more than 600
scholarly articles in top-tier journals such as Science, Nature
Reviews Microbiology, Lancet Respiratory Medicine, European Respiratory
Journal, etc. He currently holds eight patents of therapeutics for chronic
respiratory disease, three of which are currently undergoing clinical trials.
He is also a fellow of the European Respiratory Society. He was awarded the
Thoracic Society of Australia and NZ Research Medal and a Lung Legends Award
from the Australian Lung Foundation.
Dr. Philip M. Hansbro is currently the deputy director of the Centenary
Institute and Chair of Inflammation at the University of Technology Sydney.
Previously, he held academic posts at Newcastle University, University of
Cambridge and Australian National University. He obtained his bachelor’s degree
(Honours) from Sheffield Hallam University, UK, and his Ph.D. from the
University of Leeds, UK. Prof. Dr. Hansbro is one of the world’s leading
respiratory researchers with a focus on how inflammation contributes to the
progression of chronic lung diseases. As director of the Centenary UTS Centre
for Inflammation, he has led the identification of new treatments for chronic
obstructive pulmonary disease (emphysema), severe asthma, pulmonary fibrosis,
influenza, and COVID-19. Prof. Dr. Hansbro has been the world’s top-ranked researcher
on emphysema on SciVal over the past five years. He has published more than 600
scholarly articles in top-tier journals such as Science, Nature
Reviews Microbiology, Lancet Respiratory Medicine, European Respiratory
Journal, etc. He currently holds eight patents of therapeutics for chronic
respiratory disease, three of which are currently undergoing clinical trials.
He is also a fellow of the European Respiratory Society. He was awarded the
Thoracic Society of Australia and NZ Research Medal and a Lung Legends Award
from the Australian Lung Foundation.